Corporate ActionJul 21, 2026, 04:12 PM
Silexion Shareholders Approve 10M Share Capital Increase
AI Summary
Silexion Therapeutics Corp shareholders approved an increase in the company's authorized share capital by 10,000,000 ordinary shares, raising the total from 5,900,000 to 15,900,000 ordinary shares. This amendment became effective on July 21, 2026. Additionally, shareholders approved the exercisability of 399,020 Series C and D ordinary warrants and 13,966 placement agent warrants, which were issued as part of an induced warrant exercise transaction in May 2026. Both proposals were approved at the reconvened extraordinary general meeting on July 20, 2026.
Key Highlights
- Shareholders approved increasing authorized share capital by 10,000,000 ordinary shares.
- Total authorized ordinary shares increased from 5,900,000 to 15,900,000.
- Authorized share capital increased from $796,500 to $2,146,500.
- Approved exercisability of 399,020 Series C and D ordinary warrants at $5.00 per share.
- Approved exercisability of 13,966 placement agent warrants at $6.25 per share.
- New Warrant Exercisability Proposal approved with 93.3% of votes in favor.
- Authorized Share Capital Increase Proposal approved with 89.8% of votes in favor.
Price Impact
More from SLXN